Pharmacology

Cancer Treatment Data Analysis Incretin-Based Therapies Drug Development

Tovinontrine Shows Target Engagement but Fails to Lower NT‑proBNP at High Dose in Phase II

Post hoc analyses point to an inverse dose‑response that may favor lower doses and have prompted a planned Phase 2b trial in 2027 to test that hypothesis.

3 ARTICLES

this yr.

Graph AI Raises $3 Million Seed Led by Bessemer to Automate Drug Safety

3 ARTICLES

last yr.

TM3-4 Peptides Suppress Breast Cancer Growth by Targeting VIPR2 Dimers

9 ARTICLES

last yr.

Cancer drug pair extends mouse lifespan by 30% as researchers plan human trials